Close

Form 10-Q Endexx Corp For: Jun 30

August 15, 2022 2:16 PM EDT
0001109486 false --09-30 Q3 0001109486 2021-10-01 2022-06-30 0001109486 2022-08-12 0001109486 2022-06-30 0001109486 2021-09-30 0001109486 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001109486 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001109486 EDXC:SeriesZPreferredStockMember 2022-06-30 0001109486 EDXC:SeriesZPreferredStockMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember 2021-09-30 0001109486 2022-04-01 2022-06-30 0001109486 2021-04-01 2021-06-30 0001109486 2020-10-01 2021-06-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-09-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2020-09-30 0001109486 us-gaap:CommonStockMember 2020-09-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001109486 us-gaap:RetainedEarningsMember 2020-09-30 0001109486 2020-09-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2020-12-31 0001109486 us-gaap:CommonStockMember 2020-12-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001109486 us-gaap:RetainedEarningsMember 2020-12-31 0001109486 2020-12-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-03-31 0001109486 us-gaap:CommonStockMember 2021-03-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001109486 us-gaap:RetainedEarningsMember 2021-03-31 0001109486 2021-03-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-09-30 0001109486 us-gaap:CommonStockMember 2021-09-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001109486 us-gaap:RetainedEarningsMember 2021-09-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-12-31 0001109486 us-gaap:CommonStockMember 2021-12-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001109486 us-gaap:RetainedEarningsMember 2021-12-31 0001109486 2021-12-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2022-03-31 0001109486 us-gaap:CommonStockMember 2022-03-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001109486 us-gaap:RetainedEarningsMember 2022-03-31 0001109486 2022-03-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-10-01 2020-12-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2020-10-01 2020-12-31 0001109486 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001109486 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001109486 2020-10-01 2020-12-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-01-01 2021-03-31 0001109486 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001109486 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001109486 2021-01-01 2021-03-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-06-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-04-01 2021-06-30 0001109486 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001109486 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-10-01 2021-12-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-10-01 2021-12-31 0001109486 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001109486 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001109486 2021-10-01 2021-12-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2022-01-01 2022-03-31 0001109486 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001109486 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001109486 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001109486 2022-01-01 2022-03-31 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-04-01 2022-06-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2022-04-01 2022-06-30 0001109486 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001109486 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-06-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-06-30 0001109486 us-gaap:CommonStockMember 2021-06-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001109486 us-gaap:RetainedEarningsMember 2021-06-30 0001109486 2021-06-30 0001109486 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2022-06-30 0001109486 us-gaap:CommonStockMember 2022-06-30 0001109486 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001109486 us-gaap:RetainedEarningsMember 2022-06-30 0001109486 EDXC:BarterAgreementMember 2020-03-31 0001109486 us-gaap:MeasurementInputExercisePriceMember 2021-09-30 0001109486 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0001109486 us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0001109486 us-gaap:MeasurementInputExpectedTermMember 2020-10-01 2021-09-30 0001109486 us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001109486 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001109486 us-gaap:MeasurementInputPriceVolatilityMember 2022-06-30 0001109486 us-gaap:MeasurementInputExpectedTermMember 2021-10-01 2022-06-30 0001109486 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-10-01 2022-06-30 0001109486 EDXC:BusinessEquipmentandFixturesMember 2021-10-01 2022-06-30 0001109486 EDXC:PropertyandBuildingsMember 2021-10-01 2022-06-30 0001109486 EDXC:WholesaleMember 2022-04-01 2022-06-30 0001109486 EDXC:WholesaleMember 2021-04-01 2021-06-30 0001109486 us-gaap:RetailMember 2022-04-01 2022-06-30 0001109486 us-gaap:RetailMember 2021-04-01 2021-06-30 0001109486 EDXC:WholesaleMember 2021-10-01 2022-06-30 0001109486 EDXC:WholesaleMember 2020-10-01 2021-06-30 0001109486 us-gaap:RetailMember 2021-10-01 2022-06-30 0001109486 us-gaap:RetailMember 2020-10-01 2021-06-30 0001109486 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001109486 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001109486 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001109486 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001109486 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001109486 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001109486 us-gaap:WarrantMember 2021-10-01 2022-06-30 0001109486 us-gaap:WarrantMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember 2020-10-01 2021-09-30 0001109486 2020-10-01 2021-09-30 0001109486 us-gaap:LandMember 2022-06-30 0001109486 us-gaap:LandMember 2021-09-30 0001109486 us-gaap:BuildingMember 2022-06-30 0001109486 us-gaap:BuildingMember 2021-09-30 0001109486 us-gaap:MachineryAndEquipmentMember 2022-06-30 0001109486 us-gaap:MachineryAndEquipmentMember 2021-09-30 0001109486 EDXC:ComputerOfficeEquipmentMember 2022-06-30 0001109486 EDXC:ComputerOfficeEquipmentMember 2021-09-30 0001109486 us-gaap:LandAndBuildingMember EDXC:NoteholderCMember 2022-03-29 2022-04-02 0001109486 us-gaap:LandAndBuildingMember EDXC:NoteholderCMember 2022-04-02 0001109486 2022-04-02 0001109486 2022-03-29 2022-04-02 0001109486 EDXC:NoteholderAMember 2022-06-30 0001109486 EDXC:NoteholderAMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderAOneMember 2022-06-30 0001109486 EDXC:NoteholderAOneMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderATwoMember 2022-06-30 0001109486 EDXC:NoteholderATwoMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderAThreeMember 2022-06-30 0001109486 EDXC:NoteholderAThreeMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderAFourMember 2022-06-30 0001109486 EDXC:NoteholderAFourMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderAFiveMember 2022-06-30 0001109486 EDXC:NoteholderAFiveMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderBMember 2022-06-30 0001109486 EDXC:NoteholderBMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderBOneMember 2022-06-30 0001109486 EDXC:NoteholderBOneMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderCMember 2022-06-30 0001109486 EDXC:NoteholderCMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderGMember 2022-06-30 0001109486 EDXC:NoteholderGMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderIMember 2022-06-30 0001109486 EDXC:NoteholderIMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderJMember 2022-06-30 0001109486 EDXC:NoteholderJMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderKMember 2022-06-30 0001109486 EDXC:NoteholderKMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderKTwoMember 2022-06-30 0001109486 EDXC:NoteholderKTwoMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderAMember 2021-09-30 0001109486 EDXC:NoteholderAMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderAOneMember 2021-09-30 0001109486 EDXC:NoteholderAOneMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderATwoMember 2021-09-30 0001109486 EDXC:NoteholderATwoMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderAThreeMember 2021-09-30 0001109486 EDXC:NoteholderAThreeMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderAFourMember 2021-09-30 0001109486 EDXC:NoteholderAFourMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderAFiveMember 2021-09-30 0001109486 EDXC:NoteholderAFiveMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderBMember 2021-09-30 0001109486 EDXC:NoteholderBMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderGMember 2021-09-30 0001109486 EDXC:NoteholderGMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderIMember 2021-09-30 0001109486 EDXC:NoteholderIMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderIOneMember 2021-09-30 0001109486 EDXC:NoteholderIOneMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderITwoMember 2021-09-30 0001109486 EDXC:NoteholderITwoMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderJMember 2021-09-30 0001109486 EDXC:NoteholderJMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderKMember 2021-09-30 0001109486 EDXC:NoteholderKMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderIMember 2021-10-31 0001109486 EDXC:NoteholderIMember 2022-02-28 0001109486 EDXC:NoteholderAMember us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 EDXC:NoteholderAMember us-gaap:ConvertibleDebtMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAOneMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAOneMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderATwoMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderATwoMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAThreeMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAThreeMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFourMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFourMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFiveMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFiveMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderASixMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderASixMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderCMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderCMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderDMember us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderDMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderDOneMember us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderDOneMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderEMember us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderEMember 2021-10-01 2022-06-30 0001109486 EDXC:NoteholderFMember us-gaap:ConvertibleDebtMember 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderFMember 2021-10-01 2022-06-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAMember 2020-10-01 2021-09-30 0001109486 EDXC:NoteholderAOneMember us-gaap:ConvertibleDebtMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAOneMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderATwoMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderATwoMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAThreeMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAThreeMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFourMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFourMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFiveMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderAFiveMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderASixMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderASixMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderCMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderCMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderEMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderEMember 2020-10-01 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderFMember 2021-09-30 0001109486 us-gaap:ConvertibleDebtMember EDXC:NoteholderFMember 2020-10-01 2021-09-30 0001109486 2021-01-25 0001109486 us-gaap:SeriesAPreferredStockMember 2021-10-01 2022-06-30 0001109486 us-gaap:SeriesAPreferredStockMember 2020-10-01 2021-09-30 0001109486 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0001109486 us-gaap:PreferredStockMember EDXC:SeriesZPreferredStockMember 2021-10-01 2022-06-30 0001109486 EDXC:SeriesZPreferredStockMember 2021-10-01 2022-06-30 0001109486 2021-10-01 2021-10-31 0001109486 2022-05-01 2022-05-31 0001109486 EDXC:NoteholderJMember 2021-10-01 2021-10-31 0001109486 EDXC:NoteJMember 2022-05-31 0001109486 EDXC:NoteJMember 2022-05-01 2022-05-31 0001109486 EDXC:NoteholderFMember 2022-04-01 2022-04-30 0001109486 2019-09-30 0001109486 srt:MinimumMember 2019-09-30 0001109486 srt:MaximumMember 2019-09-30 0001109486 2021-10-31 0001109486 2022-05-31 0001109486 2022-07-01 2022-07-31 0001109486 EDXC:ConsultingAgreementMember EDXC:GoGreenGlobalEnterprisesMember 2018-05-06 2018-05-07 0001109486 EDXC:ConsultingAgreementMember EDXC:GoGreenGlobalEnterprisesMember 2018-05-07 0001109486 EDXC:JointVentureAgreementMember 2019-01-11 0001109486 2019-01-27 2019-01-28 0001109486 EDXC:KhodeLLCMember 2020-10-02 0001109486 EDXC:FiveYearEndorsementContractMember 2020-10-01 2020-10-31 0001109486 EDXC:FiveYearEndorsementContractMember EDXC:JulyOneTwoThousandTwentyFiveMember 2020-10-01 2020-10-31 0001109486 EDXC:EmplymentAgreementMember 2005-04-01 2005-04-30 0001109486 EDXC:ConsultingAgreementMember srt:MinimumMember 2021-10-01 2022-06-30 0001109486 EDXC:ConsultingAgreementMember srt:MaximumMember 2021-10-01 2022-06-30 0001109486 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember EDXC:RetailCustomerMember 2021-04-01 2022-06-30 0001109486 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember EDXC:RetailCustomerMember 2021-10-01 2022-06-30 0001109486 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember EDXC:RetailCustomerMember 2021-10-01 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:acre xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2022

 

Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from____to _______

 

Commission File Number: 000-30233

 

Endexx Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   30-0353162

(State or other jurisdiction

of incorporation or organization)

 

(IRS Employer

Identification No.)

 

38246 North Hazelwood Circle

Cave Creek, AZ 85331

(Address of principal executive offices)

 

(480) 595-6900

(Registrant’s telephone number)

 

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☒ No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 523,050,912 common shares as of August 12, 2022

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I – FINANCIAL INFORMATION  
Item 1: Financial Statements 3
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
Item 3: Quantitative and Qualitative Disclosures About Market Risk 10
Item 4: Controls and Procedures 10
     
  PART II – OTHER INFORMATION  
     
Item 1: Legal Proceedings 11
Item 1A: Risk Factors 11
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 11
Item 3: Defaults Upon Senior Securities 11
Item 4: Mine Safety Disclosures 11
Item 5: Other Information 11
Item 6: Exhibits 12

 

2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Our unaudited consolidated financial statements included in this Form 10-Q are as follows:

 

F-1 Condensed Consolidated Balance Sheets as of June 30, 2022 and September 30, 2021 (unaudited);
F-2 Condensed Consolidated Statements of Operations for the three months and nine months ended June 30, 2022 and 2021 (unaudited);
F-3 Condensed Consolidated Statements of Stockholder’s Deficit as of June 30, 2022 and 2021 (unaudited);
F-4 Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 2022 and 2021 (unaudited); and
F-5 Notes to Condensed Consolidated Financial Statements (unaudited).

 

These interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended June 30, 2022 are not necessarily indicative of the results that can be expected for the full year.

 

3

 

 

ENDEXX CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   June 30,   September 30, 
   2022   2021 
         
Assets          
Current assets          
Cash  $6,560   $20,867 
Accounts receivable, net of allowance of $58,257   235,764    50,755 
Inventory, net of allowance of $952,749 and $1,001,542, respectively   924,468    920,812 
Prepaid expenses   59,560    41,648 
Total current assets   1,226,352    1,034,082 
           
Investment in marketable securities   420    9,920 
Property and equipment, net of accumulated depreciation of $73,276 and $75,388, respectively   31,773    449,661 
Prepaid expenses   250,000    250,000 
Intangible - website domains   16,250    16,250 
Total assets  $1,524,795   $1,759,913 
           
Liabilities and Stockholders’ Deficit          
Current liabilities          
Accounts payable  $1,929,253   $1,020,464 
Customer deposit   15,182    36,705 
Accrued expenses   29,021    43,469 
Accrued interest   1,554,834    1,095,248 
Payroll and taxes payable, including related party   1,114,253    849,919 
Notes payable, net of discount of $78,290 and $10,957, respectively   1,412,737    1,201,584 
Convertible notes payable, net of discount of $40,640 and $0, respectively   5,877,582    5,452,111 
Derivative liabilities   12,843,580    1,799,354 
Total current liabilities   24,776,442    11,498,854 
           
Notes payable, net of current portion   156,900    248,200 
Total liabilities   24,933,342    11,747,054 
           
Commitments and contingencies (Note 8)   -     -  
           
Stockholders’ deficit          
Preferred stock, $0.0001 Par Value, 10,000,000 share authorized          
Series A preferred stock, 1,824,000 issued and outstanding, respectively   182    182 
Series Z preferred stock, 719,571 issued and outstanding, respectively   72    72 
Common stock, $0.0001 Par Value, 1,000,000,000 shares authorized, 521,988,324 and 486,313,058 issued and outstanding, respectively   52,199    48,631 
Additional paid-in capital   31,690,482    29,477,818 
Accumulated deficit   (55,151,482)   (39,513,844)
Total stockholders’ deficit   (23,408,547)   (9,987,141)
Total liabilities and stockholders’ deficit  $1,524,795  $1,759,913

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

ENDEXX CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2022   2021   2022   2021 
   For the three months ended   For the nine months ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
                 
Revenues  $418,151   $120,801   $947,428   $416,094 
Cost of revenues   179,650    385,097    489,029    724,650 
Inventory impairment   31,709    -    59,622    228,290 
Gross profit (loss)   206,792    (264,296)   398,777    (536,846)
                     
Operating expenses                    
Depreciation   6,638    5,100    16,838    15,300 
Advertising and promotion   94,311    1,085,311    444,255    1,444,600 
Payroll expenses   161,317    166,908    479,684    469,629 
Professional fees   405,015    355,410    1,442,346    777,317 
Research and development   2,738    3,637    21,675    7,021 
General and administrative expenses   169,766    220,236    626,864    680,199 
Total operating expenses   839,785    1,836,602    3,031,662    3,394,066 
                     
Loss from operations   (632,993)   (2,100,898)   (2,632,885)   (3,930,912)
                     
Other (income) and expense                    
Change in fair value of derivative liabilities   9,424,041    (440,417)   11,044,226    (240,216)
Financing costs and discount amortization   543,230    517,303    1,093,823    1,271,727 
Interest expenses   450,287    228,660    928,664    721,021 
Default penalty   584,738    -    584,738    91,576 
Gain from settlement of derivative liabilities   -    -    -    (865,103)
Gain on settlement of liabilities   -    -    (222,748)   - 
Gain on disposition of assets   (423,950)   -    (423,950)   - 
Total other (income) expense   10,578,346    305,546    13,004,753    979,005 
                     
Net loss  $(11,211,339)  $(2,406,444)  $(15,637,638)  $(4,909,917)
                     
Net loss per share - basic  $(0.02)  $(0.01)  $(0.03)  $(0.01)
                     
Weighted average shares outstanding - basic   504,758,044    460,035,302    500,181,299    445,401,099 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

 

 ENDEXX CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
   Preferred Stock - Series A   Preferred Stock - Series Z   Common Stock   Additional Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
                                     
Balances at September 30, 2020   7,296,000   $730    -   $-    404,908,141   $40,491   $21,010,497   $(32,705,690)  $(11,653,972)
Shares issued for private placements   -    -    -    -    4,323,695    432    202,568    -    203,000 
Shares issued for services   -    -    -    -    500,000    50    25,810    -    25,860 
Shares issued for debt settlement   -    -    -    -    26,371,210    2,637    756,048    -    758,685 
Settlement of derivative liability   -    -    -    -    -    -    1,420,444    -    1,420,444 
Shares issued for settlement of preferred stock   (5,472,000)   (548)   -    -    9,000,000    900    (352)   -    - 
Net loss   -    -    -    -    -    -    -    (1,090,227)   (1,090,227)
Balances at December 31, 2020   1,824,000   $182    -   $-    445,103,046   $44,510   $23,415,015   $(33,795,917)  $(10,336,210)
Shares issued for private placements   -    -    -    -    312,500    31    24,969    -    25,000 
Shares issued for financing   -    -    -    -    12,000,000    1,200    1,357,200    -    1,358,400 
Net loss   -    -    -    -    -    -    -    (1,413,246)   (1,413,246)
Balances at March 31, 2021   1,824,000   $182    -   $-    457,415,546   $45,741   $24,797,184   $(35,209,163)  $(10,366,056)
Shares issued for services   -    -    -    -    977,778    98    117,235    -    117,333 
Shares issued for financing   -    -    -    -    4,420,000    442    477,118    -    477,560 
Net loss   -    -    -    -    -    -    -    (2,406,444)   (2,406,444)
Balances at June 30, 2021   1,824,000   $182    -   $-    462,813,324   $46,281   $25,391,537   $(37,615,607)  $(12,177,607)
                                              
Balances at September 30, 2021   1,824,000   $182    719,571   $72    486,313,058   $48,631   $29,477,818   $(39,513,844)  $(9,987,141)
Shares issued for private placements   -    -    -    -    -    -    -    -    - 
Shares issued for services   -    -    -    -    6,211,180    621    299,379    -    300,000 
Shares issued for financing   -    -    -    -    2,562,500    256    135,557    -    135,813 
Warrants issued for financing   -    -    -    -    -    -    360,906    -    360,906 
Net loss   -    -    -    -    -    -    -    (1,647,205)   (1,647,205)
Balances at December 31, 2021   1,824,000   $182    719,571   $72    495,086,738   $49,508   $30,273,660   $(41,161,049)  $(10,837,627)
Net loss   -    -    -    -    -    -    -    (2,779,094)   (2,779,094)
Balances at March 31, 2022   1,824,000   $182    719,571   $72    495,086,738   $49,508   $30,273,660   $(43,940,143)  $(13,616,721)
Shares issued for services   -    -    -    -    4,100,000    410    155,390    -    155,800 
Shares issued for financing   -    -    -    -    8,928,571    894    293,749    -    294,643 
Warrants issued for financing   -    -    -    -    -    -    162,332    -    162,332 
Shares issued for conversion of interest   -    -    -    -    4,111,111    411    221,589    -    222,000 
Shares issued for default penalty   -    -    -    -    9,761,904    976    583,762    -    584,738 
Net loss   -    -    -    -    -    -    -    (11,211,339)   (11,211,339)
Balances at June 30, 2022   1,824,000   $182    719,571   $72    521,988,324   $52,199   $31,690,482   $(55,151,482)  $(23,408,547)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

ENDEXX CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2022   2021 
   For the nine months ended 
   June 30, 
   2022   2021 
Operating activities          
Net loss  $(15,637,638)  $(4,909,917)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   455,800    143,193 
Shares issued for financing costs   430,456    477,560 
Warrants issued for financing costs   523,238    - 
Depreciation and amortization   16,838    15,300 
Amortization of debt discount   105,447    662,477 
Change in fair value of derivative liabilities   11,044,226    (240,216)
Gain from settlement of liabilities   (222,748)   - 
Gain from settlement of derivative liabilities   -    (865,103)
Gain on disposition of assets   (423,950)   - 
Impairment expense   59,622    228,290 
Financing costs   34,682    131,690 
Default penalty   584,738    91,576 
Changes in operating assets and liabilities:          
Accounts receivable   (185,009)   (37,152)
Inventory   (63,278)   (44,424)
Prepaid expenses   42,088    (11,271)
Accounts payable   908,789    271,615 
Customer deposit   (21,523)   41,137 
Accrued expenses   (14,448)   (19,235)
Accrued interest   871,053    615,369 
Accrued interest, related party   -    64,332 
Payroll and taxes payable, primarily related party   264,334    240,704 
Net cash used in operating activities   (1,227,283)   (3,144,075)
           
Investing activities:          
Proceeds from sale of investments in marketable securities   9,500    - 
Net cash provided by investing activities   9,500    - 
           
Financing activities:          
Proceeds from sale of common stock   -    228,000 
Proceeds from convertible notes payable   999,853    1,614,234 
Proceeds from notes payable   203,623    1,340,000 
Repayment of note payable   -    (20,750)
Net cash provided by financing activities   1,203,476    3,161,484 
           
Net (decrease) increase in cash  $(14,307)  $17,409 
Cash, beginning of period   20,867    4,650 
Cash, end of period  $6,560   $22,059 
           
Cash paid for income taxes  $-   $- 
Cash paid for interest  $57,611   $41,320 
           
Supplemental schedule of non-cash investing and financing activities:          
Convertible notes and interest converted to common stock  $222,000   $758,685 
Derivative liabilities settled through conversion of convertible notes  $-   $1,420,444 
Debt discount at origination  $213,420   $68,100 
Prepaid expenses from note payable  $60,000   $- 
Accrued interest settled through note payable  $7,107   $- 
Property and equipment, net, sold for settlement of convertible note and interest payable  $401,050   $- 
Convertible notes and interest payable settled through the sale of property and equipment  $825,000   $- 
Amortization of right-of-use asset and lease liability  $-   $30,000 
Notes and interest payable settled through issuance of convertible notes  $-   $1,057,976 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

ENDEXX CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Organization and Basis of Presentation

 

We were incorporated under the laws of State of Nevada on September 5, 1997, as Micron Solutions. From 2002-2005, the Company operated as Panamed Corporation, a biotech service and licensing company. Panamed Corporation merged with Visual Board Books Inc. (VBB) in February 2005 and changed the consolidated company name to Endexx Corporation (the Company).

 

Our primary business is the manufacturing and sale of hemp products for personal use and pets. The Company has the following wholly owned subsidiaries:

 

Global Solaris Group, LLC
Greenleaf Consulting LLC
Cann Can LLC
Together One Step Closer, LLC
PhytoLabs LLC
Go Green Global Enterprises, Inc.
CBD Health Solutions
Kush, Inc.
CBD Life Brands, Inc.
Retail Pro Associates
CBD Unlimited, Inc.
Dispense Labs LLC
Khode, LLC (70% owner)

 

Basis of Presentation and Going Concern

 

The Company prepares its condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these estimates are reasonable and have been discussed with the Board of Directors; however, actual results could differ from those estimates. The operating results of the above listed wholly owned subsidiaries were consolidated with the condensed consolidated financial statements of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

F-5

 

 

Our condensed consolidated financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have sustained operating losses since inception, which raises substantial doubt about the Company’s ability to continue as a going concern.

 

As of June 30, 2022, we have a working capital deficit of $23,550,090, and an accumulated deficit of $55,151,482. During the period ended June 30, 2022, we had a net loss of $15,637,638 and cash used in operating activities of $1,227,283. The Company’s ability to continue in existence is dependent on its ability to develop additional sources of capital, and/or achieve profitable operations and positive cash flows. Management’s plans with respect to operations include the sustained and aggressive marketing of hemp cannabidiol products and raising additional capital through sales of equity or debt securities as may be necessary to pursue its business plans and sustain operations until such time as the Company can achieve profitability. Management believes that aggressive marketing combined with additional financing as necessary will result in improved operations and cash flow in 2023 and beyond. However, there can be no assurance that management will be successful in obtaining additional funding or in attaining profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

2. Summary of Significant Accounting Policies

 

The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and the interim reporting rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s latest Annual Report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments (unless otherwise indicated), necessary for a fair presentation of the financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

 

Use of Estimates

 

The Company’s financial statement preparation requires that management make estimates and assumptions which affect the reporting of assets and liabilities and the related disclosure of contingent assets and liabilities in order to report these financial statements in conformity with GAAP. Actual results could differ from those estimates.

 

Cash

 

Cash includes all highly liquid investments that are readily convertible to known amounts of cash and have original maturities at the date of purchase of three months or less. There were no cash equivalents as of June 30, 2022 and September 30, 2021.

 

The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation.

 

Accounts Receivable

 

Accounts receivable consists of invoiced and unpaid product sales. The Company records an allowance for doubtful accounts to allow for any amounts that may not be recoverable, which is based on an analysis of the Company’s prior collection experience, customer credit worthiness, and current economic trends. Accounts are considered delinquent when payments have not been received within the agreed upon terms and are written off when management determines that collection is not probable.

 

At June 30, 2022 and September 30, 2021, we recorded $58,257, respectively, for an allowance for doubtful accounts based upon management’s review of accounts receivable.

 

F-6

 

 

Inventory

 

Inventory is composed of finished goods, in-process, and raw goods inventory, valued on a first in first out basis, and includes production cost, product freight in, and packaging costs. Slow moving and obsolete inventories are written down based on a comparison of on-hand quantities to historical and projected usages.

 

The Company has authorized a consignment inventory arrangement with one of its mass retail customers. After consignment inventory has been sold by this customer, the customer notifies the Company of the sale and the Company records revenue in that accounting period. The Company authorizes the replenishment of consignment inventory based on orders placed by the customer. The Company is provided with weekly reports of consignment sales activity and balances.

 

Prepaid Expenses

 

The Company considers all items incurred for future services to be prepaid expenses. As of June 30, 2022, and September 30, 2021, the Company had $309,560 and $291,648, respectively, of future professional and advertising services to be received through the year ended September 30, 2023.

 

During March 2020, the Company entered into a barter agreement whereby it delivered $249,560 of its inventory in exchange for future advertising credits. The credits, which expire in March 2023, are valued at the lower of the Company’s cost of market value of the inventory transferred. Under the terms of the barter agreement, the Company is required to pay cash equal to a negotiated amount of the bartered advertising and use the barter credits to pay the balance. These credits are charged to expense as they are used. As of June 30, 2022, none of the barter credits have been used and have been recorded as non-current assets on the accompanying financial statements.

 

The Company assesses the recoverability of barter credits periodically. Factors considered in evaluating the recoverability include management’s plans with respect to advertising for which barter credits can be used. Any impairment losses are charged to operations as they are determinable. During the period ended June 30, 2022, the Company recorded no impairment losses related to barter credits and no barter credits were used.

 

Investment in Marketable Securities

 

During fiscal year ended September 30, 2018, the Company invested in marketable securities consisting of publicly traded stocks. These investments are recorded at fair value based on quoted prices at the end of the Company’s reporting period. Any realized or unrealized gains or losses are recognized in the accompanying statements of operations.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are based on the straight-line method over the estimated useful lives of the related assets. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in operations in the period realized.

 

Depreciation is computed on the straight-line method net of salvage value with useful lives as follows:

 

Computer equipment and software 5 years
Business equipment and fixtures 7 years
Property and buildings 39 years

 

Recoverability of Long-Lived Assets

 

The Company reviews its long-lived assets on a periodic basis, whenever events and changes in circumstances have occurred which may indicate a possible impairment. The assessment for potential impairment will be based primarily on the Company’s ability to recover the carrying value of its long-lived assets from expected future cash flows from its operations on an undiscounted basis. If such assets are determined to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fixed assets to be disposed of by sale will be carried at the lower of the then current carrying value or fair value less estimated costs to sell.

 

F-7

 

 

We amortize the cost of other intangible assets over their estimated useful lives, which range up to ten years, unless such lives are deemed indefinite. During the period ended June 30, 2022, we recorded no impairment charges related to other intangible assets.

 

Customer Deposits

 

From time-to-time the Company receives payment from wholesale customers in advance of delivering products to the customer. All such deposits are short term in nature as the Company delivers the product, unfulfilled portions, or services to the customer before the end of its next annual fiscal period. These deposits are credited to the customer against product deliveries or at the completion of the customer’s order.

 

Revenue Recognition

 

Revenue is recognized from the sale of hemp products when our performance obligation is satisfied. Our primary performance obligation (the distribution and sales of hemp products) is satisfied upon the shipment or delivery of products to our customers, which is also when control is transferred. The transfer of control of products to our customers is typically based on written sales terms that do not allow for a right of return after 30 days from the date of purchase. Revenue is recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities.

 

The following table presents the Company’s revenues disaggregated by type:

 

   For the three months ended 
   June 30, 
   2022   2021 
Wholesale  $199,409   $57,307 
Retail   219,742    63,494 
Total  $418,151   $120,801 

 

   For the nine months ended 
   June 30, 
   2022   2021 
Wholesale  $637,748   $250,187 
Retail   309,680    165,907 
Total  $947,428   $416,094 

 

Fair Value of Financial Instruments

 

In accordance with the reporting requirements of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. The Company does not have assets or liabilities measured at fair value on a recurring basis except its derivative liability.

 

Consequently, the Company did not have any fair value adjustments for assets and liabilities measured at fair value at the balance sheet dates, nor gains or losses reported in the statements of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held during the period ended June 30, 2022, except as disclosed.

 

F-8

 

 

Fair Value Measurement

 

ASC Topic 820, Fair Value Measurements, provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows:

 

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange.

 

Level 2 - Pricing inputs are other than quoted prices in active markets but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts or priced with models using highly observable inputs.

 

Level 3 - Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value.

 

The following tables present the Company’s assets and liabilities that were measured and recognized at fair value as of June 30, 2022 and September 30, 2021:

 

   Level 1   Level 2   Level 3   Total 
   June 30, 2022 
   Level 1   Level 2   Level 3   Total 
Marketable securities  $420   $-   $-   $420 
Derivative liabilities   -           -    12,843,580    12,843,580 
 Total  $420   $-   $12,843,580   $12,844,000 

 

   Level 1   Level 2   Level 3   Total 
   September 30, 2021 
   Level 1   Level 2   Level 3   Total 
Marketable securities  $9,920   $       -   $-   $9,920 
Derivative liabilities   -    -    1,799,354    1,799,354 
 Total  $9,920   $-   $1,799,354   $1,809,274 

 

A reconciliation of the changes in the Company’s Level 3 derivative liabilities at fair value is as follows:

 

Balance at September 30, 2021  $1,799,354 
Change in fair value   11,044,226 
Balance at June 30, 2022  $12,843,580 

 

From time to time, the Company enters into convertible promissory note agreements (Note 5). These notes are convertible at a fraction of the stock closing price near the conversion date. Additionally, the conversion price, as well as other terms including interest rates, adjust if any future financings have more favorable terms. The conversion features of these notes meet the definition of a derivative which therefore requires bifurcation and are accounted for as a derivative liability.

 

At September 30, 2021, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible promissory notes based on assumptions used in the Cox-Ross-Rubinstein binomial pricing model using the following weighted-average inputs: the price of the Company’s common stock of $0.05164; a risk-free interest rate of 0.05%, and expected volatility of the Company’s common stock of 95%, various estimated exercise prices, and terms under one year.

 

F-9

 

 

At June 30, 2022, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible promissory notes based on assumptions used in the Cox-Ross-Rubinstein binomial pricing model using the following weighted-average inputs: the price of the Company’s common stock of $0.02480; a risk-free interest rate of 2.51%, and expected volatility of the Company’s common stock of 640%, various estimated exercise prices, and terms under one year.

 

Convertible Instruments

 

The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

Beneficial Conversion Features

 

ASC 470-20 applies to convertible securities with beneficial conversion features that must be settled in stock and to those that give the issuer a choice in settling the obligation in either stock or cash. ASC 470-20 requires that the beneficial conversion feature should be valued at the commitment date as the difference between the conversion price and the fair market value of the common stock into which the security is convertible, multiplied by the number of shares into which the security is convertible. This amount is recorded as a debt discount and amortized over the life of the debt. ASC 470-20 further limits this amount to the proceeds allocated to the convertible instrument.

 

Research and development costs

 

Research and development costs are charged to expense as incurred and are included in operating expenses. Total research and development costs were $21,675 and $7,021 for the nine months ended June 30, 2022 and 2021, respectively.

 

F-10

 

 

Income Taxes

 

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

 

The Company follows ASC 740-10, Accounting for Uncertainty in Income Taxes. This interpretation requires recognition and measurement of uncertain income tax positions using a “more-likely-than-not” approach. The Company evaluates its tax positions on an annual basis, and as of September 30, 2021, no additional accrual for income taxes is necessary. The Company’s policy is to recognize both interest and penalties related to unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest or penalties since its inception. The Company is required to file income tax returns in the U.S. federal tax jurisdiction and in various state tax jurisdictions and the prior three fiscal years remain open for examination by federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax year.

 

Share Based Compensation

 

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the FASB ASC No. 718 and No. 505. The Company issues restricted stock to employees for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company also issues restricted stock to consultants for various services. Costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment only if there is sufficient disincentive to ensure performance or (ii) the date at which the counterparty’s performance is complete. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

 

(Loss) Income Per Share of Common Stock

 

Basic net loss/income per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented.

 

The Company had total potential additional dilutive securities outstanding at June 30, 2022 and September 30, 2021, as follows.

 

   June 30,   September 30, 
   2022   2021 
Warrants   36,225,566    20,750,000 
Convertible debt   609,515,342    139,000,018 
    645,740,908    159,750,018 

 

All convertible notes payable, by written agreement, provide for a beneficial ownership limitation cap of 4.99% shares of the total issued and outstanding common stock of the Company, at any given time.

 

Recently Issued Accounting Pronouncements

 

During the period ended June 30, 2022, there were several new accounting pronouncements issued by the FASB. Each of the other pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 

F-11

 

 

Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

 

If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements.

 

If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

 

3. Inventory

 

The Company’s inventory consisted of the following at the respective balance sheet dates:

 

   June 30,   September 30, 
   2022   2021 
Raw materials and packaging components  $394,950   $410,569 
Finished goods   1,281,036    1,187,096 
Consigned goods   105,045    224,147 
Apparel   96,186    100,542 
Less obsolescence allowance   (952,749)   (1,001,542)
 Inventory net  $924,468   $920,812 

 

4. Property and Equipment

 

The Company’s property and equipment consisted of the following at the respective balance sheet dates:

 

   June 30,   September 30, 
   2022   2021 
Land  $-   $114,200 
Building   -    305,800 
Machinery and equipment   66,264    66,264 
Computer/office equipment   38,785    38,785 
 Property and equipment, gross   105,049    525,049 
Less accumulated depreciation   (73,276)   (75,388)
 Property and equipment, net  $31,773   $449,661 

 

On April 1, 2022, the Company sold its land and building the Noteholder C. The land and building were carried at cost of $420,000 and accumulated depreciation of $18,950. The Company received consideration totaling $825,000 with $645,000 allocated to the October 2019 note payable (Note 5) and $180,000 to related accrued interest. As a result of the sale, the Company recognized a $423,950 gain on disposition of assets.

 

F-12

 

 

5. Debt

 

Notes payable

 

The Company’s notes payable as of June 30, 2022, are summarized as follows:

 

Noteholder  Origination   Maturity   Interest   Principal   Discount 
               Balances – June 30, 2022 
Noteholder  Origination   Maturity   Interest   Principal   Discount 
Noteholder A   4/9/2020    8/5/2020    22%  $25,000   $- 
Noteholder A   4/28/2020    8/5/2020    22%   105,000    - 
Noteholder A   7/9/2021    7/9/2022    12%   50,000    - 
Noteholder A   8/13/2021    8/13/2022    12%   100,000    - 
Noteholder A   9/3/2021    9/3/2022    12%   150,000    - 
Noteholder A   8/18/2021    8/18/2022    12%   25,000    - 
Noteholder B   9/2/2021    9/2/2022    12%   100,000    - 
Noteholder B   10/7/2021    10/7/2022    15%   50,000    - 
Noteholder C   4/1/2022    4/1/2023    10%   85,594    6,449 
Noteholder G   6/20/2017    8/5/2017    18%   55,353    - 
Noteholder I   6/17/2020    6/17/2050    4%   160,000    - 
Noteholder J   5/18/2022    11/18/2022    10%   625,000    71,841 
Noteholder K   8/28/2021    9/1/2022    15%   50,000    - 
Noteholder K   10/6/2021    10/6/2022    15%   66,980    - 
                  $1,647,927   $78,290 

 

The Company’s notes payable as of September 30, 2021, are summarized as follows:

 

Noteholder  Origination   Maturity   Interest   Principal   Discount 
               Balances - September 30, 2021 
Noteholder  Origination   Maturity   Interest   Principal   Discount 
Noteholder A   4/9/2020    8/5/2020    22%  $25,000   $- 
Noteholder A   4/28/2020    8/5/2020    22%   105,000    - 
Noteholder A   7/9/2021    7/9/2022    12%   50,000    - 
Noteholder A   8/13/2021    8/13/2022    12%   100,000    - 
Noteholder A   9/3/2021    9/3/2022    12%   150,000    - 
Noteholder A   8/18/2021    8/18/2022    12%   25,000    - 
Noteholder B   9/2/2021    9/2/2022    12%   100,000    - 
Noteholder G   6/20/2017    8/5/2017    18%   55,353    - 
Noteholder I   6/17/2020    6/17/2050    4%   160,000    - 
Noteholder I   4/27/2020    4/27/2022    1%   112,888    - 
Noteholder I   3/8/2021    3/8/2026    1%   107,500    - 
Noteholder J   5/29/2021    11/29/2021    10%   420,000    10,957 
Noteholder K   8/28/2021    9/1/2022    15%   50,000    - 
                  $1,460,741   $10,957 

 

At June 30, 2022 and September 30, 2021, accrued interest related to notes payable totaled $199,074 and $105,403, respectively.

 

During October 2021, the $112,888 note payable held by Noteholder I was forgiven by the Small Business Administration.

 

During February 2022, the $107,500 note payable held by Noteholder I was forgiven by the Small Business Administration.

 

F-13

 

 

Convertible notes payable

 

The Company’s convertible notes payable as of June 30, 2022, are summarized as follows:

 

Noteholder  Origination   Maturity   Interest   Conversion  Principal   Discount   Derivative 
                  Balances – June 30, 2022 
Noteholder  Origination   Maturity   Interest   Conversion  Principal   Discount   Derivative 
Noteholder A   2/12/2019    2/11/2020    18%   Variable  $388,889   $-   $3,188,526 
Noteholder A   3/15/2019    3/14/2020    18%   Variable   222,222    -    1,822,012 
Noteholder A   4/5/2019    4/4/2020    18%   Variable   388,889    -    3,188,526 
Noteholder A   8/5/2019    8/5/2020    18%   Variable   111,111    -    911,006 
Noteholder A   3/5/2021    3/4/2022    18%  $0.054/share   300,000    -    - 
Noteholder A   1/22/2021    1/21/2022    18%  $0.054/share   1,250,000    -    - 
Noteholder A   4/2/2021    4/1/2022    18%  $0.054/share   440,000    -    - 
Noteholder C   10/11/2019    1/31/2022    12%  $0.054/share   1,356,000    -    - 
Noteholder D   10/13/2021    10/13/2022    18%  $0.054/share   555,555    15,982    - 
Noteholder D   12/9/2021    12/9/2022    18%  $0.054/share   555,556    24,658    - 
Noteholder E   11/4/2020    5/4/2021    15%  $0.059/share   100,000    -    - 
Noteholder F   5/10/2021    5/10/2022    12%  $0.08/share   250,000    -    - 
                      $5,918,222   $40,640   $9,110,070 

 

The Company’s convertible notes payable as of September 30, 2021, are summarized as follows:

 

Noteholder  Origination   Maturity   Interest   Conversion  Principal   Discount   Derivative 
                  Balances - September 30, 2021 
Noteholder  Origination   Maturity   Interest   Conversion  Principal   Discount   Derivative 
Noteholder A   2/12/2019    2/11/2020    8%   Variable  $388,889   $       -   $504,770 
Noteholder A   3/15/2019    3/14/2020    8%   Variable   222,222    -    288,440 
Noteholder A   4/5/2019    4/4/2020    8%   Variable   388,889    -    504,770 
Noteholder A   8/5/2019    8/5/2020    12%   Variable   111,111    -    144,220 
Noteholder A   3/5/2021    3/4/2022    12%  $0.054/share   300,000    -    - 
Noteholder A   1/22/2021    1/21/2022    12%  $0.054/share   1,250,000    -    - 
Noteholder A   4/2/2021    4/1/2022    12%  $0.054/share   440,000    -    - 
Noteholder C   10/11/2019    1/31/2022    12%  $0.054/share   2,001,000    -    - 
Noteholder E   11/4/2020    5/4/2021    15%  $0.059/share   100,000    -    - 
Noteholder F   5/10/2021    5/10/2022    12%  $0.08/share   250,000    -    - 
                      $5,452,111   $-   $1,442,200 

 

At June 30, 2022 and September 30, 2021, accrued interest related to convertible notes payable totaled $1,354,920 and $989,845, respectively, and the derivative liability balances related to the accrued interest totaled $3,733,510 and $357,154, respectively.

 

6. Payroll and Payroll Taxes Payable

 

The Company’s payroll and payroll taxes payable consisted of the following at the respective balance sheet dates:

 

   June 30,   September 30, 
   2022   2021 
Accrued payroll - Officer  $212,761   $95,761 
Accrued payroll - Employee   128,105    128,105 
Accrued payroll taxes   773,387    626,053 
 Total  $1,114,253   $849,919 

 

F-14

 

 

7. Stockholders’ Deficit

 

On January 25, 2021, the Company amended its articles of incorporation to increase its authorized shares to 1,000,000,000 shares and 10,000,000 shares of the Company’s common stock and preferred stock, respectively.

 

The Company’s common stock shares have equal voting rights, are non-assessable and have one vote per share. As of June 30, 2022 and September 30, 2021, the Company’s issued and outstanding common stock totaled 521,988,324 and 486,313,058, respectively.

 

The Company’s Series A Preferred Stock shares have voting rights in the ratio of 25 votes to 1 share held. During the year ended September 30, 2021, 5,472,000 shares of Series A Preferred Stock were exchanged for 9,000,000 shares of the Company’s common stock. As of June 30, 2022 and September 30, 2021, the Company’s issued and outstanding Series A Preferred Stock totaled 1,824,000, respectively.

 

The Company’s Series Z Preferred Stock shares have voting rights equal to the aggregate of all other voting rights plus 1 and each share is convertible into 100 shares of the Company’s common stock. Additionally, the Series Z Preferred Stock carries a cumulative dividend at 4.56% of the stated value, is to be paid in kind with common stock, and is payable only at the time the shares are converted to common stock. As of June 30, 2022 and September 30, 2021, the Company’s issued and outstanding Series Z Preferred Stock totaled 719,571, respectively.

 

Issuances for services

 

During October 2021, the Company issued 6,211,180 shares of common stock valued at $300,000 for services.

 

During May 2022, the Company issued 4,100,000 shares of common stock valued at $155,800 for services.

 

Issuances for financing costs

 

During October 2021, the Company and Noteholder J agreed to modify the terms of the May 2021 note payable agreement. The maturity of the note was extended from November 2021 to April 2022. In return, the Company agreed to issue Noteholder J a total of 2,562,500 shares of common stock valued at $135,813.

 

During May 2022, the Company and Noteholder J agreed to roll the May 2021 note agreement into a new $625,000 note (Note 5). In return, the Company agreed to issue Noteholder J a total of 8,928,571 shares of common stock valued at $294,643.

 

Issuance for default penalty

 

During April 2022, the Company’s common stock was no longer quoted on OTC, resulting in a default under the terms of the May 2021 note agreement with Noteholder F (Note 5). To prevent Noteholder F from triggering default provisions, the Company and Noteholder F agreed that the Company would issue 9,761,904 common shares valued at $584,738.

 

Warrants outstanding

 

During the year ended September 30, 2019, the Company issued warrants for the purchase of 20,750,000 shares of common stock in connection with convertible note issuances. These warrants expire after four years and have exercise prices ranging from $.055 to $.355.

 

During October 2021, the Company issued warrants for the purchase of 187,500 shares of common stock with a total value of $7,587 in connection with note issuances. These warrants expire after five years and have an exercise price of $0.08.

 

During December 2021, the Company issued warrants for the purchase of 10,288,066 shares of common stock with a total value of $353,319 in connection with a note issuance. The warrants expire after five years and have an exercise price of $0.06.

 

F-15

 

 

During May 2022, the Company issued warrants for the purchase of 5,000,000 shares of common stock with a total value of $162,332 in connection with a note issuance. The warrants expire after five years and have an exercise price of $0.06.

 

A summary of the status of the Company’s warrant grants as of June 30, 2022, and the changes during the period then ended is presented below:

 

            Weighted-Average 
        Weighted-Average   Remaining 
    Warrants   Exercise Price   Contractual Life 
Outstanding at September 30, 2021    20,750,000   $0.12    1.4 years 
Granted    15,475,566    0.06    5.0 years 
Exercised    -    -    - 
Expired    -    -    - 
Outstanding at June 30, 2022    36,225,566   $0.09    2.3 years 
Exercisable at June 30, 2022    36,225,566   $0.09    2.3 years 

 

8. Commitments and Contingencies

 

Serious Promotions, Inc.

 

In June 2022, Serious Promotions, Inc. filed a Petition before the American Arbitration Association seeking monetary damages against Khode, LLC, a joint venture entered into by Serious Promotions and the Company. Serious Promotions alleges that Khode failed to make certain payments of fees related to the Endorsement and License Agreement entered into by Serious Promotions and its president Khaled Mohamed Khaled (p/k/a DJ Khaled). Serious Promotions seeks $6,250,000 in damages.

 

In July 2022, Khode, joined as a party by the Company, filed counterclaims against Serious Promotions, Khaled and Impact Brokers for breach of the Endorsement and License Agreement and related violations of legal duties, seeking damages in an amount no less than $100,000,000.

 

Although this arbitration is in its early stages, the Company is confident in its position, will vigorously defend its position, and prosecute its counterclaims, and ultimately expects rulings in its favor.

 

Contracts and commitments

 

On May 7, 2018, we assumed two consulting agreements for the two principals of Go Green Global Enterprises, a Nevada Corporation, when we acquired them. The consultants provide general business services as needed by the Company, and the term of the contract is for one year and automatically renews from year to year after that, compensation is set at a monthly fee of $5,000, and a 10% perpetual fee of 10% of the gross revenues generated by the project currently under formation. The contract also has provisions for reimbursement of all expenses incurred by them in conjunction of performing their duties.

 

On January 11, 2019, we entered into a joint venture agreement with a biometric company (GFE), in conjunction with our Jamaica financial interest, Go Green Global. GFE will contribute use of its software licenses, payment solutions software, and to assist with capital raises and build all building required for redevelopment. We agreed to use of our M3Hub and Gorilla Tek Technologies globally and use of our 150 acre grow facility in Jamaica. GFE agreed to fund the purchase of the property and retrofitting of existing buildings and making the operation fully functional.

 

F-16

 

 

On January 28, 2019, we entered into an agreement with a third party to represent our products to customers, the term of the agreement is for four (4) years from the date of the contract, January 28, 2023, and has automatic four-year renewal clauses. We agreed to pay a commission of nineteen percent (19%), composed of ten percent (10%) for commission, two percent (2%) for override, and seven percent (7%) for expenses of managing and advertising the account. Within thirty (30) days of the end of the calendar year, we agreed to pay the representative a bonus for certain sales milestones if two percent (2%) of the net receipts, payable in shares of our restricted common stock.

 

From time to time, we enter into consulting agreements for our products to be represented to certain customers or geographic areas. The terms of these agreements range from one (1) to five (5) years, and some include automatic one-year renewal clauses. As part of the agreement, commissions of ten percent (10%) are paid for sales with no distributor involved, and commissions of seven percent (7%) are paid for sales with a distributor. Depending on the consultant’s performance and achievement of certain milestones, the Company also may issue a stock bonus.

 

On October 1, 2020, the Company entered into an LLC operating agreement for the formation of Khode, LLC. Pursuant to the operating agreement, the Company owns 70% of Khode, LLC. To date, the operations in Khode have been nominal and no non-controlling interest has been allocated.

 

During October 2020, the Company entered into a five-year endorsement contract with an American DJ, record executive and producer, and media personality. Pursuant to the endorsement contract, the Company is to make quarterly payments of $250,000 totaling $5,000,000 by July 1, 2025.

 

One of the Company’s subsidiaries entered into a lease agreement for retail space in Jamaica effective October 2018. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. The lease expired after 36 months in October 2021 and required monthly lease payments of $3,250 which escalate 3% per year.

 

9. Related Party Transactions

 

Todd Davis, CEO and CFO, employment agreement

 

During April 2005, the Company entered into an employment agreement with Todd Davis providing for an annual salary of $156,000. The Company’s accrued payroll and payroll taxes payable (Note 6) includes amounts owed pursuant to the employment agreement which are unpaid as of the balance sheet dates.

 

Rayne Forecast Inc. consulting agreement

 

Rayne Forecast, Inc. (RFI), an entity owned by the CEO, is a party with the Company to a Consulting Agreement, pursuant to which the CEO, through RFI, provides certain services to the Company in connection with his role as the Company’s CEO and is compensated, through RFI, for certain services rendered to the Company. Pursuant to the terms of the Consulting Agreement, as amended, the Company shall pay to the CEO a minimum fee of $50,000 up to a maximum fee of $500,000 for the CEO’s reasonable services in any merger or acquisition involving the Company. The agreement provides that any such fees are not “finder’s fees” and are not to be calculated on the basis of any percentage of the amount of any financing or the deemed monetary value of any merger or acquisition transaction. The fees may be paid in Company stock or cash depending, among other items, on the cash availability of the Company.

 

10. Significant Customers

 

For the three and nine months ended June 30, 2022, a retail customer was responsible for 41% and 18%, respectively, of the Company’s revenues. At June 30, 2022, the customer was responsible for 73% of the net accounts receivable due to the Company.

 

At September 30, 2021, the Company had no significant revenue or accounts receivable concentrations.

 

F-17

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

For a description of our significant accounting policies and an understanding of the significant factors that influenced our performance during the three months and nine months ended June 30, 2022, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (hereafter referred to as “MD&A”) should be read in conjunction with the condensed consolidated financial statements, including the related notes, appearing in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K (the “Form 10-K”).

 

Note about Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes statements that constitute “forward-looking statements.” These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “intends,” “plans,” “expects,” or “anticipates,” and do not reflect historical facts.

 

Specific forward-looking statements contained in this portion of the Quarterly Report include, but are not limited to: (i) statements that are based on current projections and expectations about the markets in which we operate, (ii) statements about current projections and expectations of general economic conditions, (iii) statements about specific industry projections and expectations of economic activity, (iv) statements relating to our future operations, prospects, results, and performance, and (v) statements that the cash on hand and additional cash generated from operations together with potential sources of cash through issuance of debt or equity will provide the Company with sufficient liquidity for the next 12 months.

 

Forward-looking statements involve risks, uncertainties, and other factors, which may cause our actual results, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results, future performance and capital requirements and cause them to materially differ from those contained in the forward-looking statements include those identified in our Registration Statement on Form 10 under Item 1A “Risk Factors”, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

 

In addition, the foregoing factors may generally affect our business, results of operations and financial position. Forward-looking statements speak only as of the date the statements were made. We do not undertake and specifically decline any obligation to update any forward-looking statements. Any information contained on our website: www.endexx.com or any other websites referenced in this Quarterly Report are not part of this Quarterly Report.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and related notes thereto included elsewhere in this report. In addition to historical financial information, the following discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, such as our plans, objectives, expectations, and intentions. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results, or other developments. Forward-looking statements are based upon estimates, forecasts, and assumptions that are inherently subject to significant business, economic, and competitive uncertainties, and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by us, or on our behalf. We disclose any obligation to update forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those discussed under “Forward-Looking Statements,” “Item 1. Overview,” and “Item 1A. Risk Factors” sections in this Report. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

 

Overview

 

We develop hemp-derived, cannabidiol-based products, each formulated to address key segments of the health and wellness market. Through our subsidiaries, we sell high-end, full-spectrum hemp-derived oils, extracts, topicals, and pet products, all with the shared purpose of supporting the potential of relief of pain and inflammation for humans and pets, through our e-commerce site www.cbdunlimited.com, as well as other online and in-store retailers. In addition to our consumer products, our Gorilla-Tek division offers a state-of the art automated dispensing system providing a secure method of distributing hemp-based products. The proprietary system enables retailers to increase sales channels without opening a physical storefront location. Complementing our retail products and Gorilla-Tek divisions, we also own and operate a number of wholly-owned subsidiaries that offer technology and consulting solutions to the hemp and CBD industry, including an easy to use “Seed-to-Shelf” compliance and inventory tracking and process management system for regulated products in a front of counter pharmacy support platform.

 

The Company was incorporated in the State of Nevada on September 5, 1997 as Micron Solutions in order to complete a merger with Shillelagh. In November 1997, Shillelagh merged with and into Micron Solutions, with Micron Solutions as the surviving entity. In 2002, Micron Solutions entered into the Exchange Agreement with PanaMed, Inc., and all of its shareholders, pursuant to which PanaMed, Inc. became the Company’s wholly-owned subsidiary. In connection with the Exchange Agreement, Micron also changed its name to PanaMed Corporation.

 

In June 2005, we filed a Certificate of Amendment to Articles of Incorporation with the Secretary of State of the State of Nevada to change our name to Endexx Corporation. At that time, we adopted our current trading symbol, “EDXC.” In September 2005, PanaMed Corporation acquired VBB, and SaaS provider, through a merger, whereby VBB merged with and into us, and we were the surviving entity. Subsequently, we operated as a diversified technology and SaaS and compliance and tracking systems company, until we shifted our focus to the hemp-derived product industry in August 2014. In October 2018, we changed our name to CBD Unlimited, Inc., and in May 2020, we changed our name back to Endexx Corporation, with CBD Unlimited, Inc., becoming our wholly-owned subsidiary. On January 25, 2021, we filed our Amended and Restated Articles of Incorporation.

 

4

 

 

Results of Operations

 

Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021

 

Revenues

 

Revenues for the three months ended June 30, 2022 were $418,151, as compared to $120,801 for the three months ended June 30, 2021, a $297,350 increase. The increase in revenue is attributable to improved supply-chain, increased consumer spending and improved marketing efforts in promoting the Company’s products.

 

We expect an increase in commercial revenue over the next 12 months as our business model is implemented and expanded and our commercial and retail accounts continue to grow and expand the products being sold in each of their retail locations. Additionally, we will continue to focus on the development of both current and new products while continuing to commercialize existing products lines.

 

Gross Profit (Loss)

 

Gross profit (loss) for the three months ended June 30, 2022 was a profit of $206,792, as compared to a loss of $(264,296) for the three months ended June 30, 2021. This $471,088 increase in gross profit was attributable to increased quarter-over-quarter revenues, lower costs of production and decreases in inventory impairment between the periods.

 

Operating Expenses

 

Operating expenses for the three months ended June 30, 2022, were $839,785, as compared to $1,836,602 for the three months ended June 30, 2021, an decrease in operating expenses of $996,817. The decrease in operating expenses over the prior period can be attributed to a significant decrease in advertising and promotional expenses.

 

We expect that operating expenses will increase over the next 12 months as our long-term growth strategy will require significant increases in personnel and facilities along with increased research and development expenses to ensure that products nearing commercialization are brought to market as quickly and as effectively. We cannot provide any assurances that our strategy will be effective.

 

Other (Income) and Expenses 

 

Other expenses for the three months ended June 30, 2022 were $10,578,346, as compared to expenses of $305,546 for the three months ended June 30, 2021, a $10,272,800 increase. This increase in other expenses is mostly attributable to a $9,424,041 increase in the fair value of derivative liabilities, $543,230 in financing costs and discount amortization, $450,287 in interest expenses and $584,738 in default penalties.

 

Derivative liabilities are a non-cash item that are associated with loans that are convertible and have variable pricing on the equivalent shares of Common Stock. At the end of each period, these derivative liabilities are valued, and the net change is recorded as a gain or loss in other expense and income.

 

Loss from Operations and Total Net Loss

 

Loss from operations for the three months ended June 30, 2022 was $632,993, as compared to loss from operations of $2,100,898 for the three months ended June 30, 2021, an improvement of $1,467,905. The improvement in loss from operations was the result of an increase in gross revenues, lower costs of revenues and marginal inventory impairment, and a decrease in operating expenses. Total net loss for the three months ended June 30, 2022 was $11,211,339, as compared to a total net loss of $2,406,444 for the three months ended June 30, 2021, an increase of $8,804,895 in total net loss, primarily attributed to an increase of $9,424,041 in the fair value of derivative liability and a gain of $432,950 in from the disposition of assets.

 

At the end of each period, derivative liabilities are valued, and the net change is recorded as a gain or loss in other expense and income.

 

We do not expect to realize net income in the near term as anticipated operational expenses are expected to increase as a result of increased research and development expenses, consulting fees, payroll expenses, and administrative costs as staffing increases. Despite management’s focus on ensuring operating efficiencies, we expect to continue to operate at a loss through fiscal 2022 only in part due to the COVID-19 pandemic. Nevertheless, we expect that, during our current fiscal year, the adverse impact of COVID-19 on our business will slowly abate, as the positivity rate in tests for COVID-19 continues to decrease along with the new infection and mortality rates and the number of people becoming vaccinated continues to increase.

 

5

 

 

Nine months ended June 30, 2022 Compared to Nine months ended June 30, 2021

 

Revenues

 

Revenues for the nine months ended June 30, 2022 were $947,428, as compared to $416,094 for the nine months ended June 30, 2021, a $531,334 increase. The increase in revenue is attributable to improved supply-chain, increased consumer spending and improved marketing efforts in promoting the Company’s products.

 

We expect an increase in commercial revenue over the next 12 months as our business model is implemented and expanded and our commercial and retail accounts continue to grow and expand the products being sold in each of their retail locations. Additionally, we will continue to focus on the development of both current and new products while continuing to commercialize existing products lines.

 

Gross Profit (Loss)

 

Gross profit (loss) for the nine months ended June 30, 2022 was a profit of $398,777, as compared to a loss of $(536,846) for the nine months ended June 30, 2021. This $935,623 improvement in gross profit was attributable to increased revenues, lower costs of inventory and significant decreases in production costs and inventory impairment between the periods.

 

Operating Expenses

 

Operating expenses for the nine months ended June 30, 2022, were $3,031,662, as compared to $3,394,066 for the nine months ended June 30, 2021, a decrease of $362,404. The decrease in operating expenses over the period can be attributed to decreases in advertising and promotional expenses which were partially offset by increases in professional fees.

 

We expect that operating expenses will increase over the next 12 months as our long-term growth strategy will require significant increases in personnel and facilities along with increased research and development expenses to ensure that products nearing commercialization are brought to market as quickly and as effectively. We cannot provide any assurances that our strategy will be effective.

 

Other (Income) and Expenses

 

Other expenses for the nine months ended June 30, 2022 were $13,004,753, as compared to other expenses of $979,005 for the nine months ended June 30, 2021, a $12,025,748 increase. This is mostly attributable to $11,044,226 in the change in fair value of derivative liabilities, $1,093,823 in financing costs and amortization, $928,664 in interest expense and $548,738 in default penalties.

 

Derivative liabilities are associated with loans that are convertible and have variable pricing on the equivalent shares of Common Stock. At the end of each period, these derivative liabilities are valued, and the net change is recorded as a gain or loss in other expense and income.

 

Loss from Operations and Total Net Loss

 

Loss from operations for the nine months ended June 30, 2022 was $2,632,885, as compared to loss from operations of $3,930,912 for the nine months ended June 30, 2021, a decrease in net loss from operations of $1,298,027. The improvement in loss from operations was the result of an increase in gross revenues, lower costs of revenues and marginal inventory impairment, and a decrease in operating expenses. Total net loss for the nine months ended June 30, 2022 was $15,637,638, as compared to a total net loss of $4,909,917 for the nine months ended June 30, 2021, an increase of $10,727,721 in total net loss, primarily attributed to an increase of $11,044,226 in the fair value of derivative liability, $1,093,823 in financing costs, and $928,664 in interest expenses.

 

At the end of each period, derivative liabilities are valued, and the net change is recorded as a gain or loss in other expense and income.

 

We do not expect to realize net income in the near term as anticipated operational expenses are expected to increase as a result of increased research and development expenses, consulting fees, payroll expenses, and administrative costs as staffing increases. Despite management’s focus on ensuring operating efficiencies, we expect to continue to operate at a loss through fiscal 2022 only in part due to the COVID-19 pandemic. Nevertheless, we expect that, during our current fiscal year, the adverse impact of COVID-19 on our business will slowly abate, as the positivity rate in tests for COVID-19 continues to decrease along with the new infection and mortality rates and the number of people becoming vaccinated continues to increase.

 

6

 

 

Liquidity and Capital Resources

 

Going Concern

 

We have incurred operating losses since inception and have negative cash flow from operations. As of June 30, 2022, we had a stockholders’ deficit of $23,408,547, a working capital deficit of $23,550,090, an accumulated deficit of $55,151,482 and incurred a net loss of $11,211,339 in the three months ended June 30, 2022. Additionally, we utilized $1,227,283 in cash for operations and utilized $9,500 in cash for investing activities during the nine months ended June 30, 2022, while we received $1,203,467 in cash from financing activities. As a result, our continuation as a going concern is dependent on our ability to obtain additional financing until we can generate sufficient cash flow from operations to meet our obligations. We intend to continue to seek additional debt or equity financing to continue our operations, but there can be no assurance that such financing will be available on terms acceptable to us, if at all.

 

Our consolidated financial statements have been prepared on a going concern basis, which implies we may not continue to meet our obligations and continue our operations for the next fiscal year. The continuation of our Company as a going concern is dependent upon our ability to obtain necessary debt or equity financing to continue operations until we begin generating positive cash flow.

 

As of June 30, 2022, we had a cash position of $6,560. We estimate our operating expenses for the near- and mid-term may continue to exceed the revenues that we may generate, and we may need to raise capital through either debt or equity offerings to continue operations. We are in the early stages of our business. We are required to fund growth from financing activities, and we intend to rely on a combination of equity and debt financings. Due to market conditions and the early stage of our operations, there is considerable risk that we will not be able to raise such financings at all, or on terms that are not overly dilutive to our existing stockholders. We can offer no assurance that we will be able to raise such funds. If we are unable to raise the funds we require for all of our planned operations, we may be forced to reallocate funds from other planned uses and may suffer a significant negative effect on our business plan and operations, including our ability to develop new products and continue our current operations. As a result, our business may suffer, and we may be forced to reduce or discontinue operations.

 

There is no assurance that we will ever be profitable or that debt or equity financing will be available to us in the amounts, on terms, and at times deemed acceptable to us, if at all. The issuance of additional equity securities by us would result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. If we are unable to obtain financing in the amounts and on terms deemed acceptable to us, we may be unable to continue our business, as planned, and as a result may be required to scale back or cease operations for our business, the result of which would be that our stockholders would lose some or all of their investment. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should we be unable to continue as a going concern.

 

Cash Flow – Operating Activities

 

For the nine months ended June 30, 2022, our cash used in operating activities amounted to an outflow of $1,227,283, compared to cash used during the nine months ended June 30, 2021 of $3,144,075. The $1,916,792 decrease in cash used in our operating activities is due to changes in the fair value of derivative liabilities, decreases in inventory impairment and loss from settlement liabilities.

 

Cash Flow – Financing Activities

 

For the nine months ended June 30, 2022, our cash provided by financing activities amounted to $1,203,476, which includes $0 in proceeds received from the sale of our Common Stock, $999,853 in proceeds from the issuance of convertible notes, and $203,623 in proceeds from the issuance of notes payable.

 

7

 

 

For the nine months ended June 30, 2021, our cash provided by financing activities amounted to $3,161,484, which includes $228,000 in proceeds received from the sale of our Common Stock, $1,614,234 in proceeds from the issuance of convertible notes, and $1,340,000 in proceeds from the issuance of notes payable.

 

Cash Flow – Investing Activities

 

Net cash used in investing activities in the nine months ended June 30, 2022 and 2021 was $9,500 and $0, respectively.

 

Accounts Receivable and Allowance for Doubtful Account Receivable

 

Accounts receivable are recorded at net realizable value. We determine provisions for uncollectible accounts, sales returns, and claims based upon factors including the credit risk and activity of specific distributors and resellers, historical trends, and other information. If we become aware of a specific distributor’s or reseller’s inability to meet its financial obligations, bad debt charges are recorded based on an overall assessment of past due accounts receivable outstanding. In the opinion of management, a provision was deemed necessary for uncollectible accounts.

 

Inventory

 

The cost of inventory using the standard cost method, which approximates actual cost based on a first-in, first-out method. Our inventories are valued at the lower of cost or net realizable value. Our inventory consists almost entirely of finished and unfinished goods, and freight, which include CBD creams, oils, capsules, and sprays. We periodically evaluate and adjust inventories for obsolescence. In the opinion of management, no provision for obsolescence is deemed necessary. As of June 30, 2022, we had approximately $924,468 of product in inventory, which was an increase of approximately $3,656, compared to approximately $920,812 at September 30, 2021. We expect the balance of inventory to increase in direct relation to the increase in sales that we expect.

 

Goodwill and Intangible Assets

 

Goodwill arises from business combinations and is generally determined as the excess of the fair value of the consideration transferred, plus the fair value of any noncontrolling interests in the acquiree, over the fair value of the net assets acquired and liabilities assumed as of the acquisition date. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but tested for impairment at least annually or more frequently if events and circumstances exists that indicate that a goodwill impairment test should be performed. We have selected September 30 as the date to perform the annual impairment test.

 

8

 

 

Intangible assets represent both indefinite lived and definite lived assets. Trademarks are deemed to have definite useful lives of ten years, are amortized, and are tested annually for impairment. Intangible assets are reported on the balance sheet at cost less accumulated amortization. We have selected September 30 as the date to perform the annual impairment test.

 

Stock-Based Compensation

 

FASB’s ASC Topic 718, Stock Compensation (formerly, FASB Statement 123R), prescribes accounting and reporting standards for all stock-based payment transactions in which employee and non-employee services are acquired. We measure the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Fair value for restricted stock awards is valued using the closing price of our Common Stock on the date of grant. For the nine months ended June 30, 2022 and 2021, we recognized stock-based compensation expense of approximately $455,800, and $143,193, respectively.

 

Off Balance Sheet Arrangements

 

As of June 30, 2022 and on June 30, 2021, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to stockholders.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

9

 

 

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

 

As a Smaller Reporting Company, we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure control and Procedures. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2022, the period covered in this Report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Inherent Limitations on the Effectiveness of Controls

 

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

 

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

10

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

In June 2022, Serious Promotions, Inc. filed a Petition before the American Arbitration Association seeking monetary damages against Khode, LLC, a joint venture entered into by Serious Promotions and us. Serious Promotions alleges that Khode failed to make certain payments of fees related to the Endorsement and License Agreement entered into by Serious Promotions and its president Khaled Mohamed Khaled (p/k/a DJ Khaled). Serious Promotions seeks $6,250,000 in damages.

 

In July 2022, Khode, joined as a party by us, filed counterclaims against Serious Promotions, Khaled and Impact Brokers for breach of the Endorsement and License Agreement and related violations of legal duties, seeking damages in an amount no less than $100,000,000.

 

Although this arbitration is in its early stages, we are confident in our position, will vigorously defend our position, and prosecute our counterclaims, and ultimately expect a ruling in our favor.

 

We know of no other material proceedings in which any of our directors, officers, or affiliates, or any registered or beneficial stockholder is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.

 

Item 1A. Risk Factors

 

We are a Smaller Reporting Company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

We issued the following shares of our Common Stock in the three months ended June 30, 2022:

 

We had issuances for Jefferson Street and Apollo Management SPV LLC.

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

N/A

 

Item 5. Other Information

 

None

 

11

 

 

Item 6. Exhibits

 

The following exhibits are filed with or incorporated by reference into this Quarterly Report.

 

Exhibit No.   Description
     
2.1**   Share Exchange Agreement by and among PanaMed, Inc and the Registrant, dated February 22, 2002
     
2.2 **   Share Exchange Agreement by and among PhytoLabs, LLC and the Registrant, dated March 1, 2017
     
2.3a**   Common Stock Share Exchange Agreement between Go Green Global Inc and the Registrant dated May 1, 2018
     
2.3b**   First Amended Common Stock Share Exchange Agreement by and among Go Green Global, Inc. and the Registrant, dated July 10, 2018
     
3.1**   Articles of Incorporation of the Registrant filed with the Secretary of State of the State of Nevada on September 5, 1997
     
3.1a**   Certificate of Amendment to the Articles of Incorporation filed with the Secretary of State of the State of Nevada on March 1, 2002
     
3.1b**   Certificate of Amendment to the Articles of Incorporation filed with the Secretary of State of the State of the State of Nevada on June 22, 2005
     
3.1c**   Certificate of Amendment to the Articles of Incorporation filed with the Secretary of State of the State of Nevada on October 25, 2018
     
3.1d**   Certificate of Amendment to the Articles of Incorporation filed with the Secretary of State of the State of Nevada on May 3, 2020
     
3.1e**   Amended and Restated Articles of Incorporation filed with the Secretary of State of the State of Nevada on January 25, 2021
     
3.2**   Amended and Restated Bylaws of the Registrant, dated January 25, 2021
     
3.3**   Certificate of Designation of Series Z Preferred filed with the Secretary of State of the State of Nevada, Dated January 1, 2021
     
4.1**   Amended Common Stock Purchase Warrant of the Registrant, dated February 1, 2019
     
4.2**   Amended Common Stock Purchase Warrant of the Registrant, dated June 5, 2019
     
4.3**   Amended Common Stock Purchase Warrant of the Registrant, dated July 7, 2019
     
4.4**   Amended Common Stock Purchase Warrant of the Registrant, dated August 1, 2019
     
4.5**   Amended Common Stock Purchase Warrant of the Registrant, dated August 12, 2019
     
4.6**   Amended Common Stock Purchase Warrant of the Registrant, dated September 15, 2019
     
4.7**   Amended Common Stock Purchase Warrant of the Registrant, dated October 5, 2019
     
4.8**   Amended Common Stock Purchase Warrant of the Registrant, dated February 5, 2020
     
4.8a^   Warrant Modification and Clarification Agreement between the Registrant and the holder of eight Common Stock Purchase Warrants, dated June 30, 2021
     
4.9#   Common Stock Purchase Warrant granted by the Registrant, dated May 10, 2010 (2,500,000 shares)
     
4.10#   Common Stock Purchase Warrant granted by the Registrant, dated May 10, 2010 (5,185,185 shares)
     
10.1**   Stock Purchase Agreement by and among Kush Inc and the Registrant, dated February 1, 2020
     
10.2**   Stock Purchase Agreement by and between CBD Life Brands, Inc. and the Registrant, dated March 1, 2020

 

12

 

 

10.3a**   Operating Agreement by and between Khode, LLC and the Registrant, dated October 1, 2020
     
10.3b**   Endorsement Agreement by and among Khode, LLC and the Registrant
     
10.4**   Stock Purchase Agreement by and among Retail Pro Associates, Inc. and the Registrant, dated April 25, 2020
     
10.5**   Sale and Distribution Agreement by and among CBD Health Solutions and the Registrant, dated January 28,2019
     
10.6**   Distribution Agreement by and among Gold Coast and the Registrant, dated February 17, 2019
     
10.7**   Sales Representative Agreement by and among Impulse Health and the Registrant, dated December 15, 2017
     
10.8**   3PL Agreement by and among Virtual Supply and the Registrant, dated August 7, 2019
     
10.9**   Electronics Payment Agreement by and among Walgreens, Inc and the Registrant dated February 5, 2019
     
10.10**   Employment Contract – Todd Davis, dated April 5, 2005
     
10.11**   Consulting Agreement between Rayne Forecast Inc and the Registrant, dated September 1, 2001
     
10.11a**   Amended Consulting Agreement between Rayne Forecast Inc and the Registrant, dated October 1, 2009
     
10.12^   Securities Purchase Agreement between the Registrant and an investor, dated October 11, 2019
     
10.13^   Security Agreement between the Registrant and an investor, dated October 11, 2019
     
10.14^   Senior Secured Convertible Promissory Note of the Registrant in the principal amount of $750,000, dated October 19, 2019
     
10.15^   Senior Secured Convertible Promissory Note of the Registrant in the principal amount of $700,000, dated November 1, 2019
     
10.16^   Senior Secured Convertible Promissory Note of the Registrant in the principal amount of $550,000, dated January 16, 2020
     
10.17^   Update Agreement between the Registrant and an investor in respect of the Senior Secured Convertible Promissory Notes dated October 10, 2019, November 1, 2019, and January 16, 2020
     
10.18^   Convertible Note Purchase Agreement between the Registrant and an institutional investor, dated January 22, 2021
     
10.19^   Security Agreement between the Registrant and an institutional investor, dated January 22, 2021
     
10.20^   Intellectual Property Security Agreement between the Registrant and an institutional investor, dated January 22, 2021
     
10.21^   Registration Rights Agreement between the Registrant and an institutional investor, dated January 22, 2021
     
10.22^   Senior Secured Convertible Promissory Note of the Registrant in the principal amount of $1,250,000, dated January 22, 2021
     
10.23^   Common Stock Purchase Warrant of the Registrant exercisable for up to 10,416,667 shares of the Registrant’s common stock, granted on January 22, 2021
     
10.24^   Percentage Payment Agreement between the Registrant and a third party, dated January 22, 2021
     
10.25^   Senior Secured Convertible Promissory Note of the Registrant in the principal amount of $300,000, dated March 5, 2021
     
10.26^   Common Stock Purchase Warrant of the Registrant exercisable for up to 3,111,111 shares of the Registrant’s common stock, granted on March 5, 2021
     
10.27#   Securities Purchase Agreement of the Registrant, dated May 10, 2021 ($386,400)
     
10.28#   Promissory Note of the Registrant, dated May 10, 2021 ($386,400)
     
10.29#   Securities Purchase Agreement of the Registrant, dated May 10, 2021 ($750,000)

 

13

 

 

10.30#   Promissory Note of the Registrant, dated May 10, 2021 ($250,000)
     
10.31#   Registration Rights Agreement, dated May 10, 2021
     
10.32@   Exchange Agreement between Rayne Forecast, Inc., and the Registrant, effective as of September 30, 2021
     
10.33@   Exchange Agreement between Todd Davis and the Registrant, effective as of September 30, 2021
     
11.1**   Audit Committee Charter
     
11.2**   Compensation Committee Charter
     
11.3**   Corporate Governance and Nominating Committee Charter
     
21.1**   List of Subsidiaries
     
31.1*   Certification of the President and Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of the President and Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
x. 101.INS   Inline XBRL Instance Document
     
Ex. 101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
Ex. 101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
Ex. 101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
Ex. 101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
Ex. 101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*- Filed Herewith.

 

** - Filed as exhibits with equivalent exhibit numbers to our Registration Statement on Form 10, filed with the Commission on March 4, 2021, each of which is incorporated herein by reference thereto.

 

^ - Filed as exhibits with equivalent exhibit numbers to our Pre-Effective Amendment No. 1 to our Registration Statement on Form 10, filed with the Commission on April 8, 2021, each of which is incorporated herein by reference thereto.

 

# - Filed as exhibits with equivalent exhibit numbers to our Quarterly Report on Form 10-Q for our fiscal quarter ended March 31, 2021, filed with the Commission on May 24, 2021, each of which is incorporated herein by reference thereto.

 

@ - Filed as exhibits with equivalent exhibit numbers to our Annual Report on Form 10-K for our fiscal year ended September 30, 2021, filed with the Commission on March 31, 2022, each of which is incorporated herein by reference thereto.

 

14

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ENDEXX Corporation

 

August 15, 2022 By: /s/ Todd Davis
    Todd Davis
    Chief Executive Officer, Chief Financial Officer
    (Principal Executive Officer)
    (Principal Financial Officer)

 

15

 

 

Exhibit 31.1

 

I, Todd Davis, certify that;

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Endexx Corporation (the “registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

/s/ Todd Davis  
Todd Davis  
President, Chief Executive Officer,  
Chief Financial Officer, Secretary and Chairman and Director  

 

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Endexx Corporation (the “Company”) on Form 10-Q for the three months ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd Davis, the President and Chief Executive Officer and Chief Financial Officer of the Company, to the best of my knowledge and belief, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Todd Davis  
Todd Davis  
President and Chief Executive Officer and Chief Financial Officer  
(Principal Executive Officer)  
(Principal Financial Officer)  

 

Dated: August 15, 2022

 

The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report as a separate disclosure document of the Company or the certifying officers.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings